We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Charles River Laboratories International Inc | NYSE:CRL | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
3.58 | 1.56% | 233.47 | 238.38 | 232.18 | 233.61 | 466,193 | 01:00:00 |
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has extended its longstanding integrated drug discovery alliance with Genentech, a member of the Roche Group.
“We are proud to work with Genentech to identify early-stage molecules that will ultimately result in innovative treatments for patients,” said John Montana, Executive Director, Integrated Drug Discovery at Charles River. “Our long-term collaboration with Genentech has been mutually beneficial for both companies. As our teams have demonstrated, when biotechs and CROs work together, they have the ability to enhance innovations in early discovery research.”
Through this alliance, Charles River provides Genentech early discovery services, including medicinal chemistry, in vitro and in vivo biology, structural biology, and computer-aided drug design, to help identify promising candidates for preclinical development.
Charles River and Genentech have engaged in an ongoing program since 2005, with the latest extension providing a three-year continuation. The program began with a single project involving medicinal chemistry, and has evolved over the past 11 years to a multi-disciplinary collaboration drawing on Charles River’s leading researchers in chemistry, biology and pharmacology.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161011005232/en/
Charles River Laboratories International, Inc.Investor Contact:Susan E. Hardy, 781-222-6190Corporate Vice President, Investor Relationssusan.hardy@crl.comorMedia Contact:Amy Cianciaruso, 781-222-6168Corporate Vice President, Public Relationsamy.cianciaruso@crl.com
1 Year Charles River Laboratories Chart |
1 Month Charles River Laboratories Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions